SARASOTA, FL -- (MARKET WIRE) -- October 16, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that KBI BioPharma, Inc., Good Manufacturing Practices manufacturer of PT-401 for the Company’s DNAPrint Pharmaceuticals division, has completed and validated a third analytical method using a specially developed isoelectric focusing (IEF) method to be used on PT-401, the dimeric Erythropoietin fusion protein for treating anemia that is currently in preclinical stage.
